Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Characterization of GLYATL1 in Prostate Cancer

Key clinical point: The study characterizes the expression of glycine-N-acyltransferase like 1 (GLYATL1) in prostate cancer (PCa) and explores the regulation of its regulation in prostate cancer showing role for androgen and ETS transcription factor ETV1.

Major finding: GLYATL1 is overexpressed in primary prostate cancer compared with metastatic prostate cancer and benign prostatic tissue, and low-grade cancers had higher GLYATL1 expression compared to high-grade prostate tumors.

Study details: A silico analysis of cancer gene expression profiling and transcriptome sequencing to evaluate GLYATL1 expression in PCa was performed, as well as immunohistochemistry using specific GLYATL1 antibody using high-density PCa tissue microarray containing primary and metastatic PCa.


Eich ML, et al. Prostate. 2019 Aug 2. doi: 10.1002/pros.23887.